Steps to Help Protect Eligible Patients

Phone icon

EDUCATE

Identify appropriate patients and discuss their unique risks for severe RSV based on age and/or their specific underlying conditions.

RECOMMEND

Review the benefits and risks of AREXVY and strongly recommend vaccination for appropriate patients based on their medical history and/or age, and emphasize the latest CDC RSV vaccination recommendation, including for those aged 60-74 years at increased risk for severe RSV disease.*

SUPPORT

Communicate that patient attestation is sufficient evidence of the presence of a risk factor.1 Vaccinators should not deny RSV vaccination to a person because of lack of medical documentation. Additionally, address patient questions about cost and ensure insurance benefits are verified.

VACCINATE

Establish a plan that works for your patient to ensure they receive AREXVY at their local pharmacy or in office. If referring to the pharmacy, remind patients to clearly communicate their age and/or risk factors with the pharmacist and follow up to make sure they have been vaccinated.

Remember, you play a pivotal role in helping patients get vaccinated.

Remind patients to highlight their risk for severe RSV when requesting AREXVY at their local pharmacy.

*Please see the full list of CDC-identified risk factors for severe RSV disease.

#1 in RSV vaccine doses administered to adults 60 years and older.2*

Over 9.6 million adults 60 years and older vaccinated against RSV-LRTD with AREXVY as of March 2025.

*Retail claims July 2023-March 2025; retail making up majority of RSV market.

†Based on data of total retail pharmacy prescriptions in the US from July 2023 through March 2025, showing 9.64 million prescriptions for AREXVY.

Vaccinating with AREXVY is a conversation worth having.

It's important to start the conversation now about AREXVY with your appropriate unvaccinated patients.

  • Review RSV and its potential risks
  • Discuss the option of vaccination today

Patient Counseling Information

Male AREXVY patient
  • Inform vaccine recipients of the potential benefits and risks of vaccination with AREXVY
  • Inform vaccine recipients about the potential for adverse reactions that have been observed following administration of AREXVY
  • Provide the Vaccine Information Statements, which are available free of charge on the CDC website

 

GO TO THE CDC WEBSITE

LEARN MORE ABOUT COVERAGE AND CODING

Indication & Important Safety Info

Indication

Important Safety Information

Indication

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

  • individuals 60 years of age and older;
  • individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.

Important Safety Information

  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
  • In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
  • In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
  • There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
  • Vaccination with AREXVY may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

CDC=Centers for Disease Control and Prevention; RSV=respiratory syncytial virus; RSV-LRTD=respiratory syncytial virus-associated lower respiratory tract disease.

References

  1. RSV vaccine guidance for older adults. Centers for Disease Control and Prevention. Accessed March 14, 2025. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html
  2. Data on file, GSK.

Questions About AREXVY?

Call: 1-877-AREXVY1 (1-877-273-9891) Available Monday - Friday 8:30 am - 5:30 pm ET